Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biogen
7
×
biotech
boston blog main
7
×
boulder/denver blog main
boulder/denver top stories
cancer
7
×
detroit blog main
detroit top stories
indiana blog main
indiana top stories
life sciences
national
national blog main
national top stories
new york blog main
7
×
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
7
×
texas top stories
wisconsin blog main
wisconsin top stories
boston top stories
startups
alzheimer's disease
cancer immunotherapy
deals
novartis
clinical trials
eli lilly
fda
ipo
medicare
pfizer
What
bio
roundup
drug
alzheimer’s
companies
covid
gene
ipo
medicines
new
price
prices
talk
acquisitions
activity
alliance
announced
annual
approval
approvals
assessed
attention
becker
billions
biogen
biogen’s
biopharmaceutical
biotech
bristol
buy
calls
ceo
changing
clamped
collabs
color
communities
conference
convo
crispr
Language
unset
Current search:
biogen
×
" texas blog main "
×
cancer
×
" new york blog main "
×
" boston blog main "
×
@xconomy.com
3 years ago
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
5 years ago
Bio Roundup: Michael Becker, Suzanne Eaton, Gene Therapy Moves & More
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Puzzle, ESMO Assessed, Drug Prices & More